Skip to content

Drug review finds mixed results for alcohol intake and related harms

Pooled alcohol intake showed no statistically significant difference, while alcohol-related events and liver outcomes showed favorable associations.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

This abstract-based review found no statistically significant pooled difference in alcohol intake with these medicines. It also found associations with fewer alcohol-related events and liver-related outcomes. Because the evidence combined randomized trials with observational studies, those associations do not establish that the medicines caused fewer harms or are effective treatments for alcohol use.

Keep in mind

Most included studies were observational. The abstract does not specify follow-up durations or define the grouped alcohol-related and liver-related outcomes, limiting interpretation of their clinical meaning.

THE NUMBERS, WITH CONTEXT

What researchers found

SMD −0.17; 95% CI −0.39 to 0.04

Alcohol intake

Compared with controls; follow-up unspecified. The standardized mean difference expresses intake in standard-deviation units, not drinks. The negative estimate favors lower intake, but the confidence interval includes no difference.

Drug Alcohol Depend, 2025 · Original source ↓

Different summaries, different signals

The narrative summary described lower alcohol intake and less binge drinking in some evidence. The pooled intake analysis did not establish a difference. Heavy-drinking findings were mixed, and progression to cirrhosis did not differ significantly.

Separate intake from harm

Alcohol consumption, alcohol-related events, and liver outcomes answer different questions. Favorable event findings cannot substitute for evidence that drinking decreased. The authors called for stronger studies to establish whether these medicines are effective.

CHECK THE ORIGINAL

The original publication

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis.

de Faria Moraes B, André Pedral Diniz Leite G, André Pedral Diniz Leite G et al.
Drug Alcohol Depend · 2025

PubMed ID
40845737
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.